Background: Determining lung cancer (LC) risk using personalized risk stratification may improve screening effectiveness. While the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) is a well-established stratification model for LC screening, it was derived from a predominantly Caucasian population and its effectiveness in a safety net hospital (SNH) population is unknown. We have developed a model more tailored to the SNH population and compared its performance to the PLCO model in a SNH setting. Methods: Retrospective dataset was compiled from patients screened for LC at SNH from 2015 to 2019. Descriptive statistics were calculated using the following variables: age, sex, race, education, body mass index (BMI), smoking history, personal cancer history, family LC history, chronic obstructive pulmonary disease (COPD), and emphysema. Variables distribution was compared using t- and chi-square tests. LC risk scores were calculated using SNH and PLCO models and categorized as low (scores 1.5%). Linear regression was applied to evaluate the relationship between models and covariates. Results: Of 896 individuals, 38 were diagnosed with LC. Data reflected the SNH patient demographics, which predominantly were African American (53.5%), current smokers (69.9%), and with emphysema (70.1%). Among the non-LC cohort, SNH model most frequently categorized patients as low risk, while PLCO model most frequently classified patients as moderate risk. Among the LC cohort, there was no significant difference between mean scores or risk stratification. SNH model showed 92.1% sensitivity and 96.8% specificity while PLCO model showed 89.4% sensitivity and 26.1% specificity. Emphysema demonstrated a strong association in SNH model (P<0.001) while race showed no relation. Conclusions: SNH model demonstrated greater specificity for characterizing LC risk in a SNH population. The results demonstrated the importance of study sample representation when identifying risk factors in a stratification model.
In the care of lung cancer patients, early diagnosis followed by timely therapeutic procedures can have a significant impact on overall survival and patient anxiety. While robotic-assisted lung resection is now a widely accepted surgical approach, robotic-assisted bronchoscopy is a more recent diagnostic procedure that improves reach, stability, and precision in the field of bronchoscopic lung nodule biopsy. The ability to combine lung cancer diagnostics with curative-intent surgical resection into a single-setting anesthesia procedure has the potential to decrease costs, improve patient experiences, and most importantly, reduce delays in cancer care. In addition, with the expected adoption of sublobar resection for stage I lung cancer ≤2cm, combining robotic-assisted bronchoscopy with robotic surgery offers a single-setting pathway to take advantage of the precision biopsy and localization technique offered by robotic-assisted bronchoscopy and the precision operation offered by robotic surgery. We herein describe our approach to this single-setting procedure. While limited studies suggest that the combined approach results in shorter overall operative time and cost, we need future work to better characterize the overall operative time, complication rates, long-term oncologic outcomes, and cost analysis.
Background: As sub-lobar resection becomes acceptable for lung cancer ≤2 cm, a preoperative marker of tumor aggressiveness to choose an appropriate extent of resection becomes necessary. We sought to assess the utility of Computer-Aided Nodule Assessment and Risk Yield (CANARY), a validated radiomic tool, in clinical stage I adenocarcinoma ≤2 cm. Methods: We performed a retrospective review of resected lung cancer patients from 2016–2022. Our eligibility criteria included clinical stage I adenocarcinoma, availability of pre-operative computed tomography (CT) imaging, and a lesion size of ≤2 cm. Preoperative imaging was input into the CANARY program, and this was then used to categorize each lesion into good, intermediate, and poor. Kaplan-Meier curve was used to compare the recurrence-free survival (RFS). Descriptive statistics and log-rank tests were conducted to compare RFS between risk groups. Results: Study population (n=134) had a median age of 68.6 and follow up of 2.9 years. By CANARY profile, 29 patients (21.6%) were good risk, 52 (38.8%) intermediate, and 53 (39.6%) poor. By procedure, 52 patients (38.8%) received wedge resections. Overall, the 3-year RFS was 96.3%, 92.0%, and 72.7% for patients with good, intermediate, and poor risks, respectively. There was a statistically significant difference in RFS between each risk group (χ2=12.6, P=0.002). Patients with poor risk were associated with a significantly increased risk of recurrence relative to those with good/intermediate risks [hazard ratio (HR) =5.7, 95% confidence interval (CI): 1.9–17.5]. Conclusions: Poor risk on CANARY analysis is significantly associated with increased risk of recurrence after resection in clinical stage I adenocarcinoma lesions ≤2 cm.